Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: The Business Research Company | PRODUCT CODE: 1387805

Cover Image

PUBLISHER: The Business Research Company | PRODUCT CODE: 1387805

Antivirals Global Market Report 2024

Published: Pre-Order
PAGES: 175 Pages
DELIVERY TIME: 2-10 business days
SELECT AN OPTION
PDF (Single User License)
USD 5000
PDF (Site License)
USD 7500
PDF (Enterprise License)
USD 10000

Add to Cart

“Antivirals Global Market Report 2024 ” from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on antivirals market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
  • Understand how the market has been affected by the COVID-19 and how it is responding as the impact of the virus abates.
  • Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
  • Measure the impact of high global inflation on market growth.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for antivirals? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? “The antivirals market global report ” from The Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include:

The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.

The impact of higher inflation in many countries and the resulting spike in interest rates.

The continued but declining impact of COVID-19 on supply chains and consumption patterns.

  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:

  • 1) By Type: Branded; Generic
  • 2) By Drug Class: DNA Polymerase Inhibitors; Reverse Transcriptase Inhibitors; Protease Inhibitors; Neuraminidase Inhibitors; Other Drug classes
  • 3) By Application: HIV; Hepatitis; Herpes; Influenza; Other Applications
  • Companies Mentioned: AbbVie Inc.; Bristol-Myers-Squibb Co.; Chemical Industrial & Pharmaceutical Laboratories Ltd.; F. Hoffmann-La Roche Ltd.; Gilead Sciences Inc.
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery format: PDF, Word and Excel Data Dashboard.

Executive Summary

Anti-viral drug therapy encompasses the use of medications to combat viral infections, including diseases like human immunodeficiency virus (HIV), hepatitis, influenza, and emerging viruses like the novel COVID-19. These drugs work by inhibiting the replication and spread of viruses rather than directly killing them. The anti-viral drug sector primarily comprises establishments engaged in the production of various classes of antiviral drugs, including DNA polymerase inhibitors, reverse transcriptase inhibitors, protease inhibitors, neuraminidase inhibitors, and others.

The primary categories of anti-viral drug therapy include branded and generic medications. These drugs belong to different classes tailored for specific viral infections, including HIV, hepatitis, herpes, influenza, and more. Among these, reverse-transcriptase inhibitors (RTIs) are a noteworthy class used for treating HIV and, in some cases, hepatitis B infections.

The anti-viral drug therapy market research report is one of a series of new reports from The Business Research Company that provides anti-viral drug therapy market statistics, including anti-viral drug therapy industry global market size, regional shares, competitors with an anti-viral drug therapy market share, detailed anti-viral drug therapy market segments, market trends and opportunities, and any further data you may need to thrive in the anti-viral drug therapy industry. This anti-viral drug therapy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The antivirals market size has grown strongly in recent years. It will grow from $97.72 billion in 2023 to $105.73 billion in 2024 at a compound annual growth rate (CAGR) of 8.2%. The growth observed in the historical period of the anti-viral drug therapy market can be attributed to several key factors. These include the prevalence of viral diseases, growing public health concerns, patent expirations in the pharmaceutical industry, and government initiatives aimed at addressing viral infections.

The antivirals market size is expected to see strong growth in the next few years. It will grow to $143.83 billion in 2028 at a compound annual growth rate (CAGR) of 8.0%. The anticipated growth in the forecast period for the anti-viral drug therapy market can be attributed to various factors. These include the emergence of new viral threats, ongoing global health initiatives, and the adoption of technological advances. Additionally, trends such as the expansion of telemedicine and digital health, as well as the development of personalized medicine, are expected to contribute to market growth.

The rising incidence of influenza is expected to drive the growth of the antiviral market. Influenza, commonly known as the flu, is a highly contagious viral respiratory infection caused by influenza viruses. Antiviral medications are used to treat influenza by inhibiting the replication and spread of these viruses within the body. For example, in the 2021-2022 flu season, there were 9 million flu cases, 4 million flu-related medical visits, 100,000 flu-related hospitalizations, and 5,000 flu-related deaths, as reported by the Centers for Disease Control and Prevention. This increasing incidence of influenza is a key factor contributing to the growth of the antiviral market.

The growth of the anti-viral drug therapy market is expected to be driven by the increasing public-private funding for life science research on a global scale. Currently, there are no approved drugs or vaccines for the treatment of COVID-19, but there are multiple vaccines and drugs in various stages of development. Governments worldwide have allocated substantial grant funds to support research in the areas of vaccines, treatments, and diagnostics for COVID-19. For instance, in June 2021, several US government agencies and organizations, including the U.S. Department of Health and Human Services (HHS), the National Institutes of Health (NIH), the National Institute of Allergy and Infectious Diseases (NIAID), and the Biomedical Advanced Research and Development Authority (BARDA), invested over $3 billion in the research, development, and production of antiviral medications for COVID-19 as part of the Antiviral Program for Pandemics. Additionally, in October 2021, The Bill & Melinda Gates Foundation invested $120 million to support the development and manufacturing of antiviral drugs for COVID-19. This increased funding for life science research will accelerate research and development efforts, thereby promoting the growth of the market for COVID-19 antiviral drug therapy.

The market for antiviral drugs is being adversely affected by the emergence of alternative therapies such as naturopathy and homeopathy for the treatment of viral infections. The development of antiviral drugs for conditions like COVID-19 is associated with significant research and development (R&D) costs, high operational expenses, and substantial capital investments. Due to the substantial R&D expenses associated with drug development, there is a growing demand for alternative forms of treatment, including naturopathy and homeopathy. For instance, saikosaponins (A, B2, C, and D) are naturally occurring triterpene glycosides found in medicinal plants like Bupleurum spp., Heteromorpha spp., and Scrophularia scorodonia, and they have demonstrated antiviral activity against HCV-22E9. Saikosaponins work by inhibiting viral attachment and penetration stages. In contrast, marketed antiviral drugs are often priced significantly higher than their actual manufacturing costs. As a result, the availability and use of naturopathy and homeopathy medicines can pose a restraint on the growth of the antiviral drug market.

Companies operating in the antiviral drug therapy market are actively engaged in innovation driven by technological advancements to develop drugs targeting various viral infections. Biopharmaceutical companies are at the forefront of vaccine development for novel COVID-19 treatments. Technological progress in the pharmaceutical sector includes the creation of nucleic acid vaccines, which are based on DNA and RNA and enable the human body to generate vaccine antigens. For example, in October 2021, Merck & Co. Inc., a US-based pharmaceutical company, in collaboration with Ridgeback Biotherapeutics, a US-based biotechnology company, introduced Oral Antiviral Molnupiravir. This oral antiviral medication is intended for COVID-19 treatment and was granted emergency use authorization by the US Food and Drug Administration (FDA). Molnupiravir is an orally administered nucleoside analog designed to inhibit the replication of SARS-CoV-2, the virus responsible for COVID-19. This development reflects the industry's commitment to leveraging technological advances to address viral infections effectively.

Major companies operating in the antiviral market are committed to innovation, developing products such as PAXLOVID to provide reliable services to their customers. PAXLOVID is an antiviral pill used for the treatment of mild-to-moderate COVID-19. In November 2021, Pfizer Inc., a prominent US-based pharmaceutical company, introduced PAXLOVID after receiving approval from the US Food and Drug Administration (FDA). PAXLOVID is a crucial antiviral therapy that effectively treats COVID-19, reducing the risk of hospitalization and death. It is a combination therapy comprising two separate medications packaged together including nirmatrelvir and ritonavir. This innovation represents a significant step in combating COVID-19 and other viral infections.

In June 2022, Pfizer Inc., a leading US-based pharmaceutical company, completed its acquisition of ReViral Ltd. for $525 million. This strategic acquisition is part of Pfizer's effort to expand its anti-infective pipeline and strengthen its dedication to developing medications and vaccines for combating respiratory syncytial virus (RSV). ReViral Ltd., a UK-based company, specializes in the development of antiviral drugs. This acquisition enhances Pfizer's position in the fight against viral infections, particularly RSV, and represents a significant investment in the development of antiviral treatments.

Major companies operating in the antivirals market include AbbVie Inc., Bristol-Myers-Squibb Co., Chemical Industrial & Pharmaceutical Laboratories Ltd., F. Hoffmann-La Roche Ltd., Gilead Sciences Inc., GlaxoSmithKline Plc, Johnson & Johnson Services Ltd., Merck & Co. Inc., Dr. Reddy's Laboratories Ltd., AstraZeneca plc, Aurobindo Pharma Ltd., Abbott Laboratories, Schering-Plough Corporation, Pfizer Inc., Sanofi-Synthelabo Ltd., Regeneron Pharmaceuticals Inc., Inovio Pharmaceuticals Inc., Novavax Inc., BioCryst Pharmaceuticals Inc., Alnylam Pharmaceuticals Inc., Argos Distributors Limited, AVI Biopharma International Ltd., Moderna Inc., BioNTech SE, Eli Lilly and Company, Takeda Pharmaceutical Company Limited, Biogen Inc., Genentech USA Inc., Vertex Pharmaceuticals Inc.

North America was the largest region in the anti-viral drug therapy market in 2023. The Middle East is expected to be the fastest-growing region in the antivirals market during the forecast period. The regions covered in the antivirals market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the antivirals market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada

The anti-viral drug therapy market consists of sales of amantadine and rimantadine. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Product Code: r9047

Table of Contents

1. Executive Summary

2. Antivirals Market Characteristics

3. Antivirals Market Trends And Strategies

4. Antivirals Market - Macro Economic Scenario

  • 4.1. Impact Of High Inflation On The Market
  • 4.2. Ukraine-Russia War Impact On The Market
  • 4.3. COVID-19 Impact On The Market

5. Global Antivirals Market Size and Growth

  • 5.1. Global Antivirals Market Drivers and Restraints
    • 5.1.1. Drivers Of The Market
    • 5.1.2. Restraints Of The Market
  • 5.2. Global Antivirals Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
  • 5.3. Global Antivirals Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Antivirals Market Segmentation

  • 6.1. Global Antivirals Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Branded
  • Generic
  • 6.2. Global Antivirals Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • DNA Polymerase Inhibitors
  • Reverse Transcriptase Inhibitors
  • Protease Inhibitors
  • Neuraminidase Inhibitors
  • Other Drug classes
  • 6.3. Global Antivirals Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • HIV (human immunodeficiency virus)
  • Hepatitis
  • Herpes
  • Influenza
  • Other Applications

7. Antivirals Market Regional And Country Analysis

  • 7.1. Global Antivirals Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 7.2. Global Antivirals Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Antivirals Market

  • 8.1. Asia-Pacific Antivirals Market Overview
  • Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Antivirals Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.3. Asia-Pacific Antivirals Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.4. Asia-Pacific Antivirals Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Antivirals Market

  • 9.1. China Antivirals Market Overview
  • 9.2. China Antivirals Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.3. China Antivirals Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.4. China Antivirals Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Antivirals Market

  • 10.1. India Antivirals Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.2. India Antivirals Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.3. India Antivirals Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Antivirals Market

  • 11.1. Japan Antivirals Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.2. Japan Antivirals Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.3. Japan Antivirals Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Antivirals Market

  • 12.1. Australia Antivirals Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.2. Australia Antivirals Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.3. Australia Antivirals Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Antivirals Market

  • 13.1. Indonesia Antivirals Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.2. Indonesia Antivirals Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.3. Indonesia Antivirals Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Antivirals Market

  • 14.1. South Korea Antivirals Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.2. South Korea Antivirals Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.3. South Korea Antivirals Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Antivirals Market

  • 15.1. Western Europe Antivirals Market Overview
  • 15.2. Western Europe Antivirals Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.3. Western Europe Antivirals Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.4. Western Europe Antivirals Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Antivirals Market

  • 16.1. UK Antivirals Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.2. UK Antivirals Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.3. UK Antivirals Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Antivirals Market

  • 17.1. Germany Antivirals Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.2. Germany Antivirals Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.3. Germany Antivirals Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Antivirals Market

  • 18.5. France Antivirals Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.6. France Antivirals Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.7. France Antivirals Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Antivirals Market

  • 19.9. Italy Antivirals Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.10. Italy Antivirals Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.11. Italy Antivirals Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Antivirals Market

  • 20.13. Spain Antivirals Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.14. Spain Antivirals Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.15. Spain Antivirals Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Antivirals Market

  • 21.1. Eastern Europe Antivirals Market Overview
  • 21.2. Eastern Europe Antivirals Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.3. Eastern Europe Antivirals Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.4. Eastern Europe Antivirals Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Antivirals Market

  • 22.1. Russia Antivirals Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.2. Russia Antivirals Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.3. Russia Antivirals Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Antivirals Market

  • 23.1. North America Antivirals Market Overview
  • 23.2. North America Antivirals Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.3. North America Antivirals Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.4. North America Antivirals Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Antivirals Market

  • 24.1. USA Antivirals Market Overview
  • 24.2. USA Antivirals Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.3. USA Antivirals Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.4. USA Antivirals Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Antivirals Market

  • 25.1. Canada Antivirals Market Overview
  • 25.2. Canada Antivirals Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.3. Canada Antivirals Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.4. Canada Antivirals Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Antivirals Market

  • 26.1. South America Antivirals Market Overview
  • 26.2. South America Antivirals Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.3. South America Antivirals Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.4. South America Antivirals Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Antivirals Market

  • 27.1. Brazil Antivirals Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.2. Brazil Antivirals Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.3. Brazil Antivirals Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Antivirals Market

  • 28.1. Middle East Antivirals Market Overview
  • 28.2. Middle East Antivirals Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.3. Middle East Antivirals Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.4. Middle East Antivirals Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Antivirals Market

  • 29.1. Africa Antivirals Market Overview
  • 29.2. Africa Antivirals Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.3. Africa Antivirals Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.4. Africa Antivirals Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Antivirals Market Competitive Landscape And Company Profiles

  • 30.1. Antivirals Market Competitive Landscape
  • 30.2. Antivirals Market Company Profiles
    • 30.2.1. AbbVie Inc.
      • 30.2.1.1. Overview
      • 30.2.1.2. Products and Services
      • 30.2.1.3. Strategy
      • 30.2.1.4. Financial Performance
    • 30.2.2. Bristol-Myers-Squibb Co.
      • 30.2.2.1. Overview
      • 30.2.2.2. Products and Services
      • 30.2.2.3. Strategy
      • 30.2.2.4. Financial Performance
    • 30.2.3. Chemical Industrial & Pharmaceutical Laboratories Ltd.
      • 30.2.3.1. Overview
      • 30.2.3.2. Products and Services
      • 30.2.3.3. Strategy
      • 30.2.3.4. Financial Performance
    • 30.2.4. F. Hoffmann-La Roche Ltd.
      • 30.2.4.1. Overview
      • 30.2.4.2. Products and Services
      • 30.2.4.3. Strategy
      • 30.2.4.4. Financial Performance
    • 30.2.5. Gilead Sciences Inc.
      • 30.2.5.1. Overview
      • 30.2.5.2. Products and Services
      • 30.2.5.3. Strategy
      • 30.2.5.4. Financial Performance

31. Global Antivirals Market Competitive Benchmarking

32. Global Antivirals Market Competitive Dashboard

33. Key Mergers And Acquisitions In The Antivirals Market

34. Antivirals Market Future Outlook and Potential Analysis

  • 34.1 Antivirals Market In 2028 - Countries Offering Most New Opportunities
  • 34.2 Antivirals Market In 2028 - Segments Offering Most New Opportunities
  • 34.3 Antivirals Market In 2028 - Growth Strategies
  • 34.3.1 Market Trend Based Strategies
  • 34.3.2 Competitor Strategies

35. Appendix

  • 35.1. Abbreviations
  • 35.2. Currencies
  • 35.3. Historic And Forecast Inflation Rates
  • 35.4. Research Inquiries
  • 35.5. The Business Research Company
  • 35.6. Copyright And Disclaimer
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!